Corvus Pharmaceuticals, Inc.CRVSNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Trend
Trending higher, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
7.38%
Near historical average
Average (39q)
6.75%
Historical baseline
Range
High:110.54%
Low:-60.64%
CAGR
-6.3%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | 7.38% |
| Q2 2025 | 5.64% |
| Q1 2025 | 24.76% |
| Q4 2024 | 14.40% |
| Q3 2024 | 26.93% |
| Q2 2024 | 0.96% |
| Q1 2024 | 1.90% |
| Q4 2023 | 0.86% |
| Q3 2023 | -0.08% |
| Q2 2023 | -13.63% |
| Q1 2023 | 12.60% |
| Q4 2022 | -60.64% |
| Q3 2022 | 110.54% |
| Q2 2022 | -3.47% |
| Q1 2022 | 6.52% |
| Q4 2021 | -31.51% |
| Q3 2021 | -23.23% |
| Q2 2021 | 10.64% |
| Q1 2021 | 14.45% |
| Q4 2020 | 8.64% |
| Q3 2020 | -15.76% |
| Q2 2020 | -22.69% |
| Q1 2020 | 13.93% |
| Q4 2019 | -0.84% |
| Q3 2019 | -15.45% |
| Q2 2019 | 12.96% |
| Q1 2019 | 12.21% |
| Q4 2018 | 0.24% |
| Q3 2018 | -13.80% |
| Q2 2018 | -19.73% |
| Q1 2018 | 24.93% |
| Q4 2017 | -9.74% |
| Q3 2017 | -13.35% |
| Q2 2017 | -8.23% |
| Q1 2017 | 47.82% |
| Q4 2016 | 18.48% |
| Q3 2016 | 8.26% |
| Q2 2016 | 31.91% |
| Q1 2016 | 9.94% |
| Q4 2015 | 95.27% |